source
- Marrow extracts $120M series B to advance preclinical blood disease therapyA new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.